Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Rheological Effects of L-Glutamine in Patients with Sickle Cell Disease

Celeste K. Kanne, BA, Varun Reddy, Vivien A. Sheehan, MD PhD

Blood (2019) 134 (Supplement_1): 3567.

https://doi.org/10.1182/blood-2019-128891

Published: 2019

Journal Articles

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Ugochi Olivia Ogu, MD, Merin Thomas, NP, Florence Chan, PharmD, Gracy Sebastian, NP, Caterina P. Minniti, MD

Blood (2019) 134 (Supplement_1): 2287.

https://doi.org/10.1182/blood-2019-126666

Published: 2019

Journal Articles

Synthetic Platelets for Treatment of Traumatic Hemorrhage and Thrombocytopenia

Anirban Sen Gupta, PhD

Blood (2019) 134 (Supplement_1): SCI-37.

https://doi.org/10.1182/blood-2019-121079

Published: 2019

Journal Articles

Risk-Benefit and Cost-Effectiveness of Universal Iron Interventions for Public Health Control of Anemia in Young Children in 78 Countries: A Microsimulation Study

Sant-Rayn Pasricha, MD PhD, Adrian Gheorghe, PhD, Fayrouz Ashour, Amrita Arcot, BS, Laura E Murray-Kolb, PhD, Parmi Suchdev, MD MPH, Michael Bode, PhD

Blood (2018) 132 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2018-99-117611

Published: 2018

Journal Articles

Apavac, a Simple Autologous Vaccination Process (AV) Associated with Clinical Efficacy in 56 Patients (pts) Having Cancer (C) and 11 Pts Having Hematological Malignancies (HM)

Jean-Francois Rossi, MD PhD, Nicole Rouquet, PhD, Patrick Frayssinet, MD PhD

Blood (2018) 132 (Supplement 1): 5690.

https://doi.org/10.1182/blood-2018-99-118862

Published: 2018

Journal Articles

Wheatgrass Extract (Mugineic Acid): An Inexpensive and Effective Iron Chelator in Patients with Myelodysyplastic Syndromes

David P. Steensma, MD

Blood (2017) 130 (Supplement 1): 5305.

https://doi.org/10.1182/blood.V130.Suppl_1.5305.5305

Published: 2017

Journal Articles

Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events

Yutaka Niihara, MD, Rafael Razon, MD, Suvankar Majumdar, MD, Brian Claggett, PhD, Onyinye C. Onyekwere, MD, Alan Ikeda, MD, Tammuella Singleton, MD, Andrew Kohei Wood, MS, Rajani Singh, BS, Lan Tran, MPH, Charles William Stark, PharmD

Blood (2017) 130 (Supplement 1): 685.

https://doi.org/10.1182/blood.V130.Suppl_1.685.685

Published: 2017

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

Preliminary Characterization of Occipodins, Natural Product Anticoagulants from Hematophagous Marine Parasites, Isopod Elthusa vulgaris and Copepod Phrixocephalus Cincinnatus.

Alexander M. Urry, Alexandra N. Filkins, Shana K. Goffredi, PhD, Aram M Nersissian, William J Reeves

Blood (2016) 128 (22): 1443.

https://doi.org/10.1182/blood.V128.22.1443.1443

Published: 2016

Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2016) 128 (22): 850.

https://doi.org/10.1182/blood.V128.22.850.850

Published: 2016

Journal Articles

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

W Jeffrey Edenfield, MD, Bassam Mattar, MD, Stephen P Anthony, DO, Peter Mutch, Brian Chanas, Mark Smith

Blood (2015) 126 (23): 4857.

https://doi.org/10.1182/blood.V126.23.4857.4857

Published: 2015

Journal Articles

Comparative Safety of Two Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution, and a Lyophilized Powder: Results from a Phase 1 Study

Bassam Mattar, MD, Stephen P Anthony, DO, W Jeffrey Edenfield, MD, Mark Smith, Adrian Hepner

Blood (2015) 126 (23): 4861.

https://doi.org/10.1182/blood.V126.23.4861.4861

Published: 2015

Journal Articles

Mechanism of Action of an Autovaccine Against Canine DLBCL Lymphoma Leading to a Long Overall Survival

Patrick Frayssinet, MD PhD ScD, Nicole Rouquet, PhD, Laura Marconato, Federica Rossi, DVM

Blood (2014) 124 (21): 5499.

https://doi.org/10.1182/blood.V124.21.5499.5499

Published: 2014

Journal Articles

User Preference Study Of Reconstitution Systems For Factor VIII Products

Kate Khair, PhD, Gabriele Giersdorf, Patricia Guillon, Orie Ono, Lea Kalweit, Brenda Riske

Blood (2013) 122 (21): 1674.

https://doi.org/10.1182/blood.V122.21.1674.1674

Published: 2013

Journal Articles

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Jawed Fareed, Ph.D., Michael J Moorman, III, Walter Jeske, Ph.D., Debra Hoppensteadt, Ph.D.

Blood (2013) 122 (21): 4804.

https://doi.org/10.1182/blood.V122.21.4804.4804

Published: 2013

Journal Articles

Shelf-Life Extension Of Azacitidine: A Cancer Centre Experience On Waste and Cost Reduction In The Treatment Of Myelodysplastic Syndromes

Hany R. Guirguis, MD, Flay Charbonneau, BSc Pharm, Ivan Tyono, BSc Pharm, Matthew C. Cheung, MD, Rena Buckstein, MD

Blood (2013) 122 (21): 1749.

https://doi.org/10.1182/blood.V122.21.1749.1749

Published: 2013

Journal Articles

Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD, MS, Alan F. List, MD, H. Jean Khoury, MD, Anjali Advani, MD, Elias Jabbour, MD, Hagop M Kantarjian, MD, Jeffrey E Lancet, MD, LouAnn Cable, MS, Kari Guthrie, Grant Hogeland, PhD, Mieke Ptaszynski, MD, Lara Maloney, BA, Donald Corson, Rami S. Komrokji, MD

Blood (2013) 122 (21): 387.

https://doi.org/10.1182/blood.V122.21.387.387

Published: 2013

Journal Articles

Discovery and Characterization of Chemical Inhibitors of UBC13.

Charitha Madiraju, PhD, Shu-ichi Matsuzawa, PhD, Robert Ardecky, PhD, Ian Pass, PhD, Tram Ngo, Yasuko Matsuzawa, Carina Wimer, Michael Cuddy, Paul Diaz, PhD, Correa Ricardo, PhD, Craig Tamble, PhD, Chih-Wen Shu, PhD, Anthony Pinkerton, PhD, Eduard Sergienko, PhD, Chris Hassig, PhD, Thomas Chung, PhD, John C. Reed, MD, PhD

Blood (2012) 120 (21): 2950.

https://doi.org/10.1182/blood.V120.21.2950.2950

Published: 2012

Journal Articles

Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614.

Shannon L Winski, PhD, LouAnn Cable, MS, Grant Hogeland, PhD, Suzy Brown, M.S., Dan Weaver, PhD, Jenn Garrus, PhD, Susan Rhodes, BS, Lara Maloney, BA, Ann Marie Ptaszynski, MD, H. Jean Khoury, MD, Mikkael A. Sekeres, MD, MS, Rami S. Komrokji, MD, Guillermo Garcia Manero, MD, David Chantry, PhD

Blood (2012) 120 (21): 2825.

https://doi.org/10.1182/blood.V120.21.2825.2825

Published: 2012

Journal Articles

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Kevin R. Kelly, MD, Swaminathan Padmanabhan, MBBS, MD, André Goy, MD, Jesus G. Berdeja, MD, Craig B. Reeder, MD, Kevin T. McDonagh, MD, Xiaofei Zhou, PhD, Hadi Danaee, SD, Hugh Xiao, PhD, Ely Benaim, MD, Thomas C. Shea, MD

Blood (2011) 118 (21): 2477.

https://doi.org/10.1182/blood.V118.21.2477.2477

Published: 2011

NARROW

Rheological Effects of L-Glutamine in Patients with Sickle Cell Disease

Barriers to the Use of Endari™ in an Urban Adult Sickle Cell Center

Synthetic Platelets for Treatment of Traumatic Hemorrhage and Thrombocytopenia

Risk-Benefit and Cost-Effectiveness of Universal Iron Interventions for Public Health Control of Anemia in Young Children in 78 Countries: A Microsimulation Study

Apavac, a Simple Autologous Vaccination Process (AV) Associated with Clinical Efficacy in 56 Patients (pts) Having Cancer (C) and 11 Pts Having Hematological Malignancies (HM)

Wheatgrass Extract (Mugineic Acid): An Inexpensive and Effective Iron Chelator in Patients with Myelodysyplastic Syndromes

Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Preliminary Characterization of Occipodins, Natural Product Anticoagulants from Hematophagous Marine Parasites, Isopod Elthusa vulgaris and Copepod Phrixocephalus Cincinnatus.

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

Comparative Safety of Two Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution, and a Lyophilized Powder: Results from a Phase 1 Study

Mechanism of Action of an Autovaccine Against Canine DLBCL Lymphoma Leading to a Long Overall Survival

User Preference Study Of Reconstitution Systems For Factor VIII Products

Defibrotide Interaction With Newer Oral Anticoagulant and Antiplatelet Drugs

Shelf-Life Extension Of Azacitidine: A Cancer Centre Experience On Waste and Cost Reduction In The Treatment Of Myelodysplastic Syndromes

Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes

Discovery and Characterization of Chemical Inhibitors of UBC13.

Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614.

Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only